What Offers Immunome (IMNM) a Compelling Investment Opportunity?
Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Immunome Inc. (IMNM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 5,558,885 | $121,572,815 | -3% | 8.05% |
| 2. | Driehaus Capital Richard Driehaus | 4,099,901 | $89,664,835 | +11% | 0.66% |
| 3. | Enavate Sciences James Boylan | 3,613,799 | $79,033,784 | -25% | 22.48% |
| 4. | SilverArc Capital Devesh Gandhi | 1,850,278 | $40,465,580 | +65% | 4.13% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,575,398 | $34,453,954 | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.27 | 1,000 | $19,270.00 | 43,415 | 2026-06-05 | Filing | |
| $19.46 | 3,500 | $68,110.00 | 42,415 | 2026-06-05 | Filing | |
| $19.48 | 6,000 | $116,880.00 | 38,915 | 2026-06-05 | Filing | |
| $20.70 | 5,000 | $103,500.00 | 43,415 | 2026-05-15 | Filing | |
| $19.67 | 25,450 | $500,601.50 | 690,704 | 2026-03-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.00 | 1,092 | $27,300.00 | 0 | 2026-07-07 | Filing | |
| $24.20 | 16,906 | $409,125.20 | 108,504 | 2026-07-07 | Filing | |
| $24.11 | 83,094 | $2,003,396.34 | 125,410 | 2026-07-06 | Filing | |
| $23.44 | 16,072 | $376,727.68 | 15,805 | 2026-07-02 | Filing | |
| $22.76 | 16,214 | $369,030.64 | 31,877 | 2026-07-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 714,553 | $15,141,378 | 1.5% | |
| 2. | 268,167 | $5,682,459 | 0.18% | |
| 3. | 44,389 | $940,603 | 0.03% | |
| 4. | 41,759 | $884,873 | 0.06% | |
| 5. | 31,090 | $658,797 | 0% |
News See All
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen
On April 30, Bloomberg reported that Steve Cohen resigned as president of Point72 Asset Management, and Harry Schwefel was appointed co-CIO.
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc.
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?
On December 15, Immunome, Inc. (NASDAQ:IMNM) shared positive topline results from the Phase 3 RINGSIDE trial, demonstrating an improved survival rate without progression, when compared with a placebo.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Jim Cramer Offered Insights on These 16 Stocks
“I need you to understand what makes my approach different from the conventional wisdom. It's all rooted in the sales and trading I did for 20 years before Mad Money started.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Michael Burry, Bill Miller, Brevan Howard Asset Management, Engine No. 1, Bright Health Group Inc (BHG), J2 Global Inc (JCOM), and More
SkyBridge Capital’s Anthony Scaramucci is stepping up his firm’s move into the cryptocurrency world, announcing on Monday a partnership aimed at expanding into the blockchain universe.